Fabrice COFFRINI / AFP via Getty Images UBS gave its highest conviction calls for 2026, laying out its top stock picks across sectors. The bank is bullish on a wide variety of companies spanning several high-growth sectors. A few of its top stocks for 2026 include Acadia Pharmaceuticals and Alliant Energy. If you're making your list of stocks to watch in the new year, UBS has a list of its highest conviction stocks for 2026 that could offer some insight. The bank released its list of top picks fo ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is expected to deliver the same efficacy and safety profile of DAYBUE oral solution, while offering children and adults living. ...

Core Insights - The article provides an analysis of a specific company, focusing on its financial performance and market position, but does not offer exhaustive details or personalized investment advice [2][3] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15%, reaching $1.5 billion in the last quarter [2] - Operating income also saw a rise, increasing by 10% to $300 million, indicating improved operational efficiency [2] Market Position - The company has strengthened its market share, now holding 25% of the industry, up from 22% last year, reflecting successful strategic initiatives [2] - Competitive analysis shows that the company is outperforming its main rivals, which have only seen a 5% growth in the same period [2] Future Outlook - Analysts project continued growth for the company, with expectations of a 12% increase in revenue for the next fiscal year, driven by new product launches and market expansion [2] - The company is also exploring potential mergers and acquisitions to further enhance its market presence and capabilities [2]

Company Overview - ACADIA Pharmaceuticals is a mid-cap biotechnology company focused on developing and commercializing therapies for central nervous system disorders, leveraging a focused pipeline and established commercial infrastructure to address significant unmet needs in neurology and psychiatry [6] - The company generates revenue primarily through the commercialization of NUPLAZID for Parkinson's disease psychosis, with an advancing pipeline that includes late-stage candidates for Alzheimer's disease psychosis and Rett syndrome [9] - As of the latest report, ACADIA's market capitalization is $4.4 billion, with a trailing twelve-month revenue of $1 billion and net income of $261.2 million [4] Recent Developments - Braidwell, a Connecticut-based fund, has established a new position in ACADIA Pharmaceuticals, acquiring nearly 2.4 million shares valued at approximately $50.8 million as of September 30, which represents 2.1% of the fund's total reportable U.S. equity assets for the quarter [2] - The stock price of ACADIA as of Wednesday is $25.88, reflecting a 59% increase over the past year, significantly outperforming the S&P 500, which has risen 13% in the same period [3] Financial Performance - ACADIA has recently delivered double-digit revenue growth, with expanding sales for both NUPLAZID and DAYBUE, and has more than doubled its net income in the third quarter [7] - The company has raised its full-year guidance and has nearly $850 million in cash on the balance sheet, positioning it well for continued growth [10] Market Position and Outlook - Despite the stock being more than 50% below its pandemic peak, the fundamentals of ACADIA appear stronger than in previous years, suggesting potential for a more durable recovery [7][12] - The confidence shown by a major biotech-focused fund stepping in indicates a positive trajectory for the company, emphasizing the importance of execution in converting late-stage assets into commercial successes [11]

Group 1 - The article does not provide any specific content related to a company or industry, as it appears to be a technical issue regarding browser settings and ad-blockers [1]

Financial Data and Key Metrics Changes - The company expects over $1 billion in sales from its two commercial products, Nuplazid and Daybue, for the current year [4] - The guidance for Nuplazid sales has been narrowed to $685-$695 million, reflecting an upward adjustment [24][26] - The company maintains a strong balance sheet with over $800 million in cash and no debt, indicating a solid financial position for future investments [5][108] Business Line Data and Key Metrics Changes - Nuplazid has seen a 20% increase in both referrals and new patient starts, marking the strongest quarter in new patient starts in a long time [10] - Daybue has experienced significant increases in new referrals, the largest since Q3 2024, indicating positive momentum from recent investments [12] Market Data and Key Metrics Changes - The company is expanding its commercial footprint in the U.S. and plans to enter the European market with expected approval next year [12][59] - The market for Alzheimer's disease psychosis (ADP) is significantly larger than that for Parkinson's disease psychosis (PDP), presenting a substantial growth opportunity [73] Company Strategy and Development Direction - The company is focused on expanding its sales force and enhancing marketing efforts for both Nuplazid and Daybue to drive growth [11][45] - The strategy includes leveraging existing data and insights to optimize targeting and positioning of the sales force for Nuplazid [16] - The company plans to market Daybue independently in Europe, building a team to support this initiative [58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued meaningful growth for both franchises, with plans to provide guidance for Nuplazid next year [31] - The company is mindful of potential impacts from legislative changes but does not anticipate significant disruptions to profitability [36][37] - Management highlighted the importance of ongoing investments in R&D and commercial operations to support long-term growth [110] Other Important Information - The company has a robust pipeline, with ACP-204 being a key focus for upcoming trials in Alzheimer's disease psychosis and Lewy body dementia psychosis [5][66] - Management emphasized the importance of patient retention and the ongoing benefits of Daybue for patients who remain on therapy [48] Q&A Session Summary Question: Can you summarize the commercial performance for Nuplazid and Daybue? - Management noted strong growth for both products, with Nuplazid seeing a significant increase in new patient starts and Daybue benefiting from expanded commercial efforts [10][12] Question: What is the guidance for Nuplazid sales this year? - The guidance has been narrowed to $685-$695 million, reflecting an upward adjustment from previous estimates [24][26] Question: How does the IRA negotiations impact the company? - Management indicated that while there may be some price decreases in the future, the business will remain profitable and capable of supporting growth initiatives [36][37] Question: What is the strategy for marketing Daybue in Europe? - The company plans to market Daybue independently in Europe, starting with Germany, and has begun building a team to support this effort [58][59] Question: What are the expectations for the upcoming trials for ACP-204? - Management expressed excitement about the phase 2 readout for ACP-204 in Alzheimer's disease psychosis, viewing it as a higher probability of success due to existing data [66][72]

Financial Data and Key Metrics Changes - The company expects over $1 billion in sales from its two commercial products, NUPLAZID and DAYBUE, for the current year [5] - NUPLAZID's sales guidance for the year has been narrowed to a range of $685 million to $695 million, indicating an upward shift from previous estimates [23][24] - The company maintains a strong balance sheet with over $800 million in cash and no debt, allowing for continued investment in business development [6][105] Business Line Data and Key Metrics Changes - NUPLAZID has seen a 20% increase in both referrals and new patient starts, marking the strongest quarter in new patient starts in a long time [10] - DAYBUE has experienced significant increases in new referrals, the largest since Q3 2024, indicating early success from increased investment in U.S. infrastructure [12] - The company plans to expand its customer-facing field force to further drive growth and profitability for both NUPLAZID and DAYBUE [11] Market Data and Key Metrics Changes - The company is preparing for European approval of DAYBUE next year, aiming to expand its market presence outside the U.S. [12][55] - The market for Alzheimer's disease psychosis (ADP) is significantly larger than that for Parkinson's disease psychosis (PDP), presenting a substantial growth opportunity [70] Company Strategy and Development Direction - The company is focused on expanding its commercial footprint and increasing investments in marketing and sales to enhance product awareness and penetration [11][12] - A robust pipeline is in place, with ACP-204 being the most advanced program targeting Alzheimer's disease psychosis and Lewy body dementia psychosis [6][61] - The company is committed to maintaining profitability while navigating potential price decreases due to future negotiations under the IRA [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued meaningful growth for both franchises, with plans to provide guidance on peak sales for NUPLAZID next year [28] - The company is mindful of potential legislative impacts but does not anticipate significant disruptions to its growth strategy in the near term [34] Other Important Information - The company has a stable patient base for DAYBUE, with over 70% of patients on therapy for 12 months or longer, indicating strong treatment adherence [40] - The company is actively building a team in Europe to prepare for the launch of DAYBUE, with a focus on establishing scientific conversations and market access [55] Q&A Session Summary Question: Can you provide an overview of the commercial performance for NUPLAZID and DAYBUE? - Management highlighted a strong quarter for NUPLAZID with a 20% increase in new patient starts and significant growth for DAYBUE due to increased referrals [10][12] Question: What is the sales guidance for NUPLAZID this year? - The sales guidance has been narrowed to a range of $685 million to $695 million, reflecting an upward adjustment [23][24] Question: How does the IRA impact the company? - Management indicated that while there may be price decreases in the future, the company expects to remain profitable and continue driving growth [34] Question: What is the strategy for expanding DAYBUE in Europe? - The company plans to market DAYBUE independently in Europe, starting with Germany, and has begun building a team to support this effort [55] Question: What are the expectations for the upcoming phase II readout for ACP-204? - Management expressed excitement about the phase II readout for ACP-204, viewing it as a higher probability of success due to prior learnings from pimavanserin [61][62]

Financial Data and Key Metrics Changes - The company expects over $1 billion in sales from its two commercial products, Nuplazid and Daybue, for the current year [5] - The guidance for Nuplazid has been narrowed to $685-$695 million, reflecting an upward shift from previous estimates [24][26] - The company maintains a strong balance sheet with over $800 million in cash and no debt, indicating a solid financial position for future investments [6][116] Business Line Data and Key Metrics Changes - Nuplazid has seen a 20% increase in both referrals and new patient starts, marking the strongest quarter in new patient starts in a long time [10] - Daybue has experienced significant increases in new referrals, the largest since the third quarter of 2024, indicating positive momentum from recent investments [12] Market Data and Key Metrics Changes - The company is expanding its commercial footprint in the U.S. and plans to enter the European market with expected approval next year [12][60] - The market for Alzheimer's disease psychosis (ADP) is significantly larger than that for Parkinson's disease psychosis (PDP), presenting a substantial growth opportunity [76] Company Strategy and Development Direction - The company is focused on expanding its customer-facing field force to enhance growth and profitability for Nuplazid [11] - There is a strategic emphasis on leveraging existing data and experience to optimize the development of ACP-204, a next-generation treatment for ADP and Lewy body dementia psychosis [67][75] - The company plans to market Daybue independently in Europe, building a team to facilitate this expansion [60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued meaningful growth for both Nuplazid and Daybue, with expectations for further guidance on peak sales for Nuplazid next year [33] - The potential impact of the Inflation Reduction Act (IRA) on pricing and profitability is acknowledged, but management believes the business will remain profitable despite anticipated price decreases [39] Other Important Information - The company has a robust pipeline with several important catalysts, including the phase 2 readout for ACP-204 expected mid-next year [6][68] - Management highlighted the importance of educating physicians about the benefits and side effects of Daybue to improve patient retention on therapy [57] Q&A Session Summary Question: What is the guidance for Nuplazid this year? - The guidance for Nuplazid is set at $685-$695 million, reflecting an upward adjustment from previous estimates [24][26] Question: How does the company plan to expand its market presence? - The company plans to expand its commercial footprint in the U.S. and enter the European market, with a focus on building a dedicated team for marketing Daybue [60] Question: What are the expectations for the upcoming phase 2 readout for ACP-204? - The phase 2 readout for ACP-204 is anticipated mid-next year, with management expressing excitement about the potential for success based on existing data [68][82]

Core Viewpoint - Acadia Pharmaceuticals Inc. will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on December 2, 2025, at 9:45 a.m. Eastern Time [1] Company Information - A live webcast of the fireside chat will be available on Acadia's website under the investors section, with an archived recording accessible for approximately one month following the presentation [1]

Summary of ACADIA Pharmaceuticals Conference Call Company Overview - **Company**: ACADIA Pharmaceuticals (NasdaqGS:ACAD) - **Focus**: Building a leading neurological and rare disease company with aspirations to become a global biotech powerhouse [2][3] Core Industry Insights - **Market Position**: ACADIA is focused on long-term growth in neurological and rare diseases, leveraging its existing product NUPLAZID for Parkinson's disease psychosis and expanding its pipeline [2][3] - **Pipeline Development**: The company is advancing several promising candidates, including ACP-204 for Alzheimer's disease psychosis and DAYBUE for Rett syndrome, with plans for global expansion [3][4] Financial Highlights - **Revenue Projections**: Expected revenues for 2025 are over $1 billion, with peak potential for NUPLAZID and DAYBUE estimated between $1.5 billion and $2 billion [4][5] - **Sales Growth**: NUPLAZID reported record sales of $177.5 million in Q3, reflecting a 12% year-over-year growth, with significant increases in prescriptions and referrals [9][10] - **DAYBUE Performance**: DAYBUE achieved over $100 million in sales in Q3, with over 1,000 patients treated globally since its launch [11][12] Pipeline and Product Development - **Key Products**: - **NUPLAZID**: First FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease, with a market share of approximately 25% [8][9] - **DAYBUE**: First treatment for Rett syndrome, with a growing diagnosis rate and strong efficacy data [10][11] - **Upcoming Milestones**: - Phase two study initiation for ACP-211 in major depressive disorder and phase one study for ACP-271 in Q1 2026 [6][20] - Anticipated CHMP opinion for DAYBUE in Q1 2026 [11][24] Strategic Focus Areas - **Precision Medicine**: Emphasis on using biomarkers in trials and integrating AI and machine learning into development processes [4] - **Global Expansion**: Strong focus on expanding operations beyond the U.S. into Europe and Japan [4] - **Patient Empowerment**: Centering patient journeys in the development and delivery of treatments [4] Unmet Medical Needs - **Alzheimer's Disease Psychosis**: Approximately 800,000-850,000 patients in the U.S. experience hallucinations or delusions, with no approved treatments available [14][17] - **Lewy Body Dementia**: A significant portion of patients (50%-70%) experience psychosis, highlighting the need for effective therapies [17][18] - **Major Depressive Disorder**: 21 million adults diagnosed in the U.S., with only 9 million currently treated, indicating a large market opportunity [19][20] Conclusion - **Future Outlook**: ACADIA is positioned for growth with a strong pipeline and financial health, aiming to address significant unmet needs in neurological and rare diseases while expanding its market presence [24]